GoodRx Holdings (GDRX) Enterprise Value (2019 - 2026)

GoodRx Holdings has disclosed Enterprise Value across 8 years of filings, most recently posting -$235.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$235.7 million, up 21.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$235.7 million (up 21.69% YoY), and the FY2025 annual result was -$261.8 million, up 41.6% from the prior year.
• Enterprise Value came in at -$235.7 million for Q1 2026 at GoodRx Holdings, up from -$261.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$235.7 million in Q1 2026 to a low of -$845.4 million in Q1 2022.
• The 5-year median for Enterprise Value is -$533.3 million (2024), against an average of -$549.2 million.
• Across the five-year window, Enterprise Value retreated 9.07% in 2023 and surged 46.69% in 2024, its largest moves.
• GoodRx Holdings' Enterprise Value stood at -$757.2 million in 2022, then gained by 11.21% to -$672.3 million in 2023, then surged by 33.31% to -$448.3 million in 2024, then surged by 41.6% to -$261.8 million in 2025, then rose by 9.97% to -$235.7 million in 2026.
• The last three Enterprise Value figures came in at -$235.7 million (Q1 2026), -$261.8 million (Q4 2025), and -$273.5 million (Q3 2025), per Business Quant data.